0 references
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review
Endocrinology Diabetes & Metabolism2025Vol. 9(1), pp. e70142–e70142
Abstract
There is considerable uncertainty about how stakeholders perceive biosimilar insulin switches, particularly managed switch programmes. Almost no literature related to the experience of stakeholders who have already engaged in biosimilar insulin switching was identified. More research is needed to provide guidance on how healthcare systems can implement biosimilar insulin switch programmes in a manner acceptable to healthcare professionals and patients.